New combo therapy targets Hard-to-Treat cancers
NCT ID NCT06915142
First seen Jan 27, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This study tests a new drug called HRS-7058 combined with other cancer drugs in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find safe doses and see if the combination shrinks tumors. About 300 adults aged 18 to 75 with good performance status are being recruited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMOUR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact
-
Tianjin Cancer Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact
Conditions
Explore the condition pages connected to this study.